Adding PCSK9 inhibitors to statins is notably beneficial in patients experiencing recent myocardial infarctions with residual multivessel coronary disease, likely due to plaque stabilization, particularly in vulnerable thin-cap fibroatheroma. The gene discussed is PCSK9; the disease is myocardial infarction.